Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.06 - $51.86 $8.5 Million - $11 Million
-212,300 Reduced 64.47%
117,000 $4.69 Million
Q2 2024

Aug 14, 2024

BUY
$36.45 - $47.7 $12 Million - $15.7 Million
329,300 New
329,300 $15.7 Million
Q3 2023

Nov 14, 2023

SELL
$38.5 - $47.13 $3.81 Million - $4.67 Million
-99,000 Reduced 76.74%
30,000 $1.36 Million
Q2 2023

Aug 14, 2023

BUY
$34.73 - $43.33 $1.56 Million - $1.95 Million
45,000 Added 53.57%
129,000 $5.29 Million
Q1 2023

May 15, 2023

BUY
$33.58 - $41.2 $1.39 Million - $1.71 Million
41,500 Added 97.65%
84,000 $3 Million
Q4 2022

Feb 14, 2023

SELL
$37.12 - $46.52 $1.39 Million - $1.74 Million
-37,500 Reduced 46.88%
42,500 $1.61 Million
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $4.38 Million - $5.84 Million
-120,000 Reduced 60.0%
80,000 $3.54 Million
Q2 2022

Aug 15, 2022

BUY
$31.71 - $43.0 $6.34 Million - $8.6 Million
200,000 New
200,000 $7.4 Million
Q1 2022

May 13, 2022

SELL
$29.88 - $37.04 $1.72 Million - $2.13 Million
-57,500 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$33.54 - $40.55 $1.09 Million - $1.32 Million
-32,500 Reduced 36.11%
57,500 $1.93 Million
Q2 2021

Aug 16, 2021

BUY
$34.54 - $47.25 $2.07 Million - $2.84 Million
60,000 Added 200.0%
90,000 $3.59 Million
Q1 2021

May 17, 2021

SELL
$42.51 - $63.78 $1.17 Million - $1.75 Million
-27,500 Reduced 47.83%
30,000 $1.35 Million
Q4 2020

Feb 16, 2021

BUY
$45.3 - $60.27 $2.6 Million - $3.47 Million
57,500 New
57,500 $3.25 Million
Q3 2019

Nov 14, 2019

SELL
$59.06 - $72.15 $2.36 Million - $2.89 Million
-40,000 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$62.09 - $86.14 $2.48 Million - $3.45 Million
40,000 New
40,000 $2.57 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.28B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.